Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00502775 · ClinicalTrials.gov registry record · Phase 4
Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 680
- Enrollment target
NCT00502775: Completed Phase 4 study, sponsored by GlaxoSmithKline.
NCT00502775 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 680 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (31% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00502775, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 680 participants
- Enrollment target
Study Summary
The primary objective of the study is to compare nighttime symptom relief of fluticasone furoate nasal spray versus oral fexofenadine
Primary Outcome
Questions include: 1. Nasal congestion on awakening (Score: 0=none, 1=mild, 2=moderate, 3=severe); 2. Difficulty going to sleep (Score: 0=not at all, 1=little, 2=moderately, 3=very); 3. Nighttime awakenings (Score: 0=not at all, 1=once, 2=more than once, 3=felt like awake all night). The sum of the ratings for the three items comprises the NSS.
Interventions
- DRUG fluticasone furoate, fexofenadine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 680 participants |
| Start Date | 2007-08 |
| Est. Completion | 2007-11 |
| Phase | Phase 4 |
What the finished NCT00502775 record still lists
NCT00502775 is an interventional study that assigns participants to a tested intervention. The registered 680 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (31% higher).
The record links to 0 conditions, and to 1 intervention - of which fluticasone furoate, fexofenadine is the first listed.
NCT00502775 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00502775 about?
NCT00502775 is a clinical study titled "Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine". The primary objective of the study is to compare nighttime symptom relief of fluticasone furoate nasal spray versus oral fexofenadine
What is the current status of trial NCT00502775?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 680 participants. The study started on 2007-08. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00502775?
The interventions under investigation include: fluticasone furoate, fexofenadine (DRUG).
Who is sponsoring clinical trial NCT00502775?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00502775's enrollment target sits among peer trials
680 119th of 2000 higher than 1,882 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03501706 · 680 participants · NA
An Assessment of Cognitive Improvement Training Among Mid-life Individuals
- NCT05626452 · 680 participants · NA
PrEP Optimization Among Women to Enhance Retention and Uptake
- NCT05753748 · 680 participants · NA
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
- NCT05952141 · 680 participants · NA
Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia